Aims-To determine the pattern of expression of the p53 tumour suppressor gene product in anal squamous neoplasia, and to determine if this could be used as a marker of disease progression. The association between p53 expression and human papillomavirus (HPV) 16 DNA status of the anal lesions was also investigated. Methods-The presence and localisation of the p53 protein in formalin fixed, paraffin wax embedded specimens of anal squamous epithelium (normal and neoplastic) was examined using immunohistochemical staining with a panel of two monoclonal antibodies (DO-1, DO-7) and one polyclonal antibody (CM-1). Thirty nine normal anal epithelia, 14 anal intraepithelial neoplasia (AIN) grade 1, seven AIN 2, and 20 AIN 3 specimens were obtained from patients without demonstrable invasive disease; twelve AIN 3 specimens adjacent to invasive disease and 34 anal squamous cancers were also examined. Genomic DNA from all 126 specimens was extracted and analysed for HPV 16 DNA using the polymerase chain reaction (PCR).
Results-Nuclear p53 was strongly expressed in 67% (23134) of invasive anal squamous tumours, 75% (9/12) of AIN 3 specimens adjacent to invasive disease, and in 60% (12120) of AIN 3 specimens obtained from patients without demonstrable invasive disease. Two of the patients in the latter group with positively staining specimens subsequently developed invasive tumours which had staining characteristics similar to those of the AIN 3 specimens. p53 protein was expressed in very low concentrations in low grade AIN and not at all in normal anal squamous epithelium. In those specimens which stained positively for p53, HPV The specimens were analysed with a panel of two monoclonal antibodies DO-1 (courtesy of Professor DP Lane) and DO-7 (Novocastra Laboratories, England) and the rabbit polyclonal antibody CM-1 (courtesy of Professor DP Lane) produced against recombinant human p53 and permitting detection of p53 in routine formalin fixed histological material.202' The antibodies were used in dilutions of 1 in 100, 1 in 2000, and 1 in 4000 for DO-7, CM-1, and DO-1, respectively. DO-1 and DO-7 recognise epitopes between amino acids 1 and 45 at the Nterminal end of both mutant and wild type p53 protein.
Sections (5 gum) were cut, floated on poly-I-lysine coated glass microscope slides, and air dried overnight at room temperature. Sections were dewaxed in xylene and hydrated through graded alcohols to deionised water. Immunohistochemical analysis was performed using a conventional three-layered streptavidin horseradish peroxidase technique. Endogenous peroxidase activity was blocked by a 5 minute incubation in 3% hydrogen peroxide, followed by incubation of the specimens in non-immune goat serum to block non-specific binding. The specimens were then incubated with the appropriate dilution of the primary antibody for 1 exclusively nuclear, weak in intensity, involving at least 5% of the dysplastic squamous epithelium (Figure) . At least 80% of the specimens stained positively with all 3 antibodies (table 2). There was no staining of the stroma and normal squamous epithelial cells in the specimens.
HIGH GRADE AIN
Analysis of p53 immunostaining in the two groups of AIN 3 specimens showed that a significant number stained positively with the p53 antibodies (table 2). In AIN 3 specimens obtained from patients without demonstrable invasive disease in the primary biopsy material, 60% (12/20) of the specimens stained positively for p53 protein. Staining was exclusively nuclear, involving over 50% of the squamous cells in seven specimens, and 10-15% of the squamous cells in five specimens (Figure) . During a mean follow up period of demonstrable invasive disease, 42-8% (3/7) of AIN 2 and 28-5% (4/14) of AIN 1 specimens. None of the specimens of normal anal epithelium was positive for HPV 16 DNA (table 3) . A total of 43-6% (55) specimens stained positively for p53. Of these, 36 were HPV 16 positive and 19 were HPV 16 negative (table 4) . Statistical analysis examining the correlation between p53 staining and the HPV DNA status in all the neoplastic anal specimens was performed using the X2 test (with a significance of p < 0.05). There was no correlation between p53 positivity and HPV 16 DNA status.
Discussion
Intraepithelial neoplastic lesions of the anus (AIN) were first described a decade ago.2' The natural history of these lesions is unknown, although possible parallels between AIN and cervical intraepithelial neoplasia (CIN) have been suggested with regard to progression to invasive squamous cell carci- The results of our study show that increased p53 protein concentrations occur in high grade AIN and invasive anal squamous cell carcinomas. The similarity in the pattern of distribution of p53 concentrations in invasive tumours and adjacent AIN 3 lesions suggest that a field effect phenomenon may be operating. Furthermore, in two specimens of AIN 3 obtained from patients without demonstrable invasive disease, which stained strongly for the p53 protein, the patients subsequently developed invasive anal squamous cell carcinomas which had a similar staining pattern to that of the AIN 3 specimens. These results suggest that mutations of the p53 gene (leading to expression of high concentration of mutant p53 protein) may have a role in the pathogenesis of anal squamous neoplasia. The accumulation of mutant p53 protein may also possibly serve as a marker of likely disease progression from AIN 3 to invasive lesions. Long term follow up of the AIN 3 lesions, however, are required to confirm these results.
These results are similar to those of studies which have examined p53 expression in squamous neoplasia at other sites. These studies have shown increased concentrations of the p53 protein in oesophageal, skin, and head and neck squamous cell carcinomas." Furthermore, some of these studies have shown a close correlation between increased concentrations of p53 protein and mutations of the p53 gene locus.33 34 Increased p53 concentrations have also been shown in dysplastic and normal epithelium obtained from patients with p53 positive invasive squamous cell carcinomas." '34 The presence of increased p53 protein concentrations in HPV positive AIN and invasive tumours (table 4) is surprising, as current evidence suggests that there is an inverse relation between the presence of p53 mutations and oncogenic HPV sequences. The E6 oncogenic protein of HPV 16 and 18 has been shown to complex with wild type p53 protein, accelerating its degradation, and thereby nullifying the tumour suppressor effects of the wild type p53 protein. '7'8 In HPV negative tumours it is thought that mutations of the p53 gene leads to loss of function of the wild type allele. The results from recent studies, however, suggest that the relation between HPV infection and p53 mutation in anogenital neoplasia may not be quite so clear cut.39 40 These studies suggest that there is no obvious association between the presence or absence of HPV sequences and mutations or allelic loss at the p53 gene locus.
We do not think that the results of the present study are due to non-specific cross reaction as antibodies to different epitopes on the p53 molecule were used. The results with these antibodies correlated strongly with each other (table 2) and were consistently repeatable. Further investigation into the status of the p53 gene in anal squamous neoplasia, however, is required. We are currently sequencing the p53 genp locus in the specimens examined in the present study.
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